Lymph Node Positivity of Axillary Reverse Mapping Lymph Nodes at the Time of Axillary Lymph Node Dissection: Two-Site Prospective Trial.
Journal
Annals of surgical oncology
ISSN: 1534-4681
Titre abrégé: Ann Surg Oncol
Pays: United States
ID NLM: 9420840
Informations de publication
Date de publication:
Oct 2023
Oct 2023
Historique:
received:
24
04
2023
accepted:
23
06
2023
medline:
12
9
2023
pubmed:
19
7
2023
entrez:
19
7
2023
Statut:
ppublish
Résumé
Axillary reverse mapping (ARM) was introduced in 2007 to identify and selectively preserve upper-extremity lymphatics during axillary lymph node surgery to decrease the risk of lymphedema. The patient population in which an ARM lymph node (LN) can be preserved during an axillary lymph node dissection (ALND) has not been established to date. This study aimed to determine the frequency of metastatic involvement of an ARM LN among patients undergoing ALND. Patients undergoing ALND with or without immediate lymphatic reconstruction (ILR) were enrolled in a prospective trial at two institutional sites between April 2018 and Decemeber 2022. This report analyzes the ARM node positivity and total LN positivity rates during ALND for the cohort of patients enrolled in the ILR intervention arm of the study. The inclusion criteria were met by 139 patients, who made up the study population (133 with breast cancer and 6 with other disease). Of the breast cancer patients, 99.2% were female, 35.3% (47/133) were cT3 or greater, and 96.2% (128/133) had cN1 or greater disease. For 55 of the 133 patients (41.4%), the ARM nodes were marked and specified in the pathology report. Of the 55 patients, 39 (70.9%) had a positive LN at ALND. Of these 55 patients, 11 (20%) had positive ARM nodes. The ARM LN was the only positive node in 3 of the 11 patients. In the contemporary patient population undergoing ALND, the positivity rate of the ARM LN was relatively high, suggesting that leaving ARM LNs in patients undergoing ALND may not be oncologically safe.
Sections du résumé
BACKGROUND
BACKGROUND
Axillary reverse mapping (ARM) was introduced in 2007 to identify and selectively preserve upper-extremity lymphatics during axillary lymph node surgery to decrease the risk of lymphedema. The patient population in which an ARM lymph node (LN) can be preserved during an axillary lymph node dissection (ALND) has not been established to date. This study aimed to determine the frequency of metastatic involvement of an ARM LN among patients undergoing ALND.
METHODS
METHODS
Patients undergoing ALND with or without immediate lymphatic reconstruction (ILR) were enrolled in a prospective trial at two institutional sites between April 2018 and Decemeber 2022. This report analyzes the ARM node positivity and total LN positivity rates during ALND for the cohort of patients enrolled in the ILR intervention arm of the study.
RESULTS
RESULTS
The inclusion criteria were met by 139 patients, who made up the study population (133 with breast cancer and 6 with other disease). Of the breast cancer patients, 99.2% were female, 35.3% (47/133) were cT3 or greater, and 96.2% (128/133) had cN1 or greater disease. For 55 of the 133 patients (41.4%), the ARM nodes were marked and specified in the pathology report. Of the 55 patients, 39 (70.9%) had a positive LN at ALND. Of these 55 patients, 11 (20%) had positive ARM nodes. The ARM LN was the only positive node in 3 of the 11 patients.
CONCLUSION
CONCLUSIONS
In the contemporary patient population undergoing ALND, the positivity rate of the ARM LN was relatively high, suggesting that leaving ARM LNs in patients undergoing ALND may not be oncologically safe.
Identifiants
pubmed: 37466868
doi: 10.1245/s10434-023-13883-9
pii: 10.1245/s10434-023-13883-9
doi:
Types de publication
Clinical Trial
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
6042-6049Informations de copyright
© 2023. Society of Surgical Oncology.
Références
Claude N, Lesieur B, Clough KB, Lecuru F. Blue dye injection in the arm in order to conserve the lymphatic drainage of the arm in breast cancer patients requiring an axillary dissection. Ann Surg Oncol. 2007;14:2490–6.
doi: 10.1245/s10434-007-9450-4
Thompson M, Korourian S, Henry-Tillman R, et al. Axillary reverse mapping (ARM): a new concept to identify and enhance lymphatic preservation. Ann Surg Oncol. 2007;14:1890–5.
doi: 10.1245/s10434-007-9412-x
pubmed: 17479341
Han C, Yang B, Zuo WS, Zheng G, Yang L, Zheng MZ. The feasibility and oncological safety of axillary reverse mapping in patients with breast cancer: a systematic review and meta-analysis of prospective studies. PloS One. 2016;11:1–16.
Boneti C, Korourian S, Diaz Z, et al. Scientific impact award: axillary reverse mapping (ARM) to identify and protect lymphatics draining the arm during axillary lymphadenectomy. Am J Surg. 2009;198:482–7.
doi: 10.1016/j.amjsurg.2009.06.008
pubmed: 19800452
Tummel E, Ochoa D, Korourian S, et al. Does axillary reverse mapping prevent lymphedema after lymphadenectomy? Ann Surg. 2017;265:987–92.
doi: 10.1097/SLA.0000000000001778
pubmed: 27163955
Ahmed M, Rubio IT, Kovacs T, Klimberg VS, Douek M. Systematic review of axillary reverse mapping in breast cancer. Br J Surg. 2016;103:170–8.
doi: 10.1002/bjs.10041
pubmed: 26661686
Beek MA, Gobardhan PD, Schoenmaeckers EJ, et al. Axillary reverse mapping in axillary surgery for breast cancer: an update of the current status. Breast Cancer Res Treat. 2016;158:421–32.
doi: 10.1007/s10549-016-3920-y
pubmed: 27444925
Rutgers EJ, Donker M, van Tienhoven G. Is there a role for axillary reverse mapping in the current management of breast cancer treatment? Eur J Surg Oncol. 2016;42:78.
doi: 10.1016/j.ejso.2015.07.001
pubmed: 26256851
Ponzone R, Tomasi Cont N, Maggiorotto F, et al. Extensive nodal disease may impair axillary reverse mapping in patients with breast cancer. J Clin Oncol. 2009;27:5547–51.
doi: 10.1200/JCO.2009.22.1846
pubmed: 19826123
Foster D, Choy N, Porter C, Ahmed S, Wapnir I. Axillary reverse mapping with indocyanine green or isosulfan blue demonstrate similar crossover rates to radiotracer identified sentinel nodes. J Surg Oncol. 2018;117:336–40.
doi: 10.1002/jso.24859
pubmed: 29228459
Noguchi M, Miura S, Morioka E, Kosaka T, et al. Is axillary reverse mapping feasible in breast cancer patients? Eur J Surg Oncol. 2015;41:442–9.
doi: 10.1016/j.ejso.2015.01.029
pubmed: 25704555
Ngui NK, French J, Kilby CJ, Pathmanathan N, Elder EE. Axillary reverse mapping in patients with breast cancer: is it oncologically safe? J Surg Oncol. 2016;113:726–31.
doi: 10.1002/jso.24231
pubmed: 27041002
Bedrosian I, Bablera GV, Mittendorf EA, et al. A phase 1 study to assess the feasibility and oncologic safety of axillary reverse mapping in breast cancer patients. Cancer. 2010;116:2543–8.
pubmed: 20336790
Beek MA, Gobardhan PD, Klompenhouwer EG, Rutten H, Voogd AC, Luiten E. Axillary reverse mapping (ARM) in clinically node-positive breast cancer patients. EJSO. 2014;41:59–63.
doi: 10.1016/j.ejso.2014.09.012
pubmed: 25468747
Khandelwal R, Poovamma CU, Shilpy C, Prema M, Anthony P. Axillary reverse mapping: Is it feasible in locally advanced breast cancer patients? Breast Disease. 2014;34:151–5.
doi: 10.3233/BD-140371
pubmed: 24934169
Giuliano AE, Ballman KV, McCall L, et al. Effect of axillary dissection vs no axillary dissection on 10-year overall survival among women with invasive breast cancer and sentinel node metastatsis: the ACOSOG Z0011 (Alliance) randomized clinical trial. JAMA. 2017;318:918–26.
doi: 10.1001/jama.2017.11470
pubmed: 28898379
pmcid: 5672806
Nguyen TT, Hoskin TL, Day CN, et al. Decreasing use of axillary dissection in node-positive breast cancer patients treated with neoadjuvant chemotherapy. Ann Surg Oncol. 2018;25:2596–602.
doi: 10.1245/s10434-018-6637-9
pubmed: 29978369
Clough KB, Nasr R, Nos C, Vieira M, Inguenault C, Poulet B. New anatomical classification of the axilla with implications for sentinel node biopsy. Br J Surg. 2010;97:1659–65.
doi: 10.1002/bjs.7217
pubmed: 20799288
Nos C, Clough KB, Bonnier P, et al. Upper outer boundaries of the axillary dissection: results of the SENTIBRAS protocol: multicentric protocol using axillary reverse mapping in breast cancer patients requiring axillary dissection. Eur J Surg Oncol. 2016;42:1827–33.
doi: 10.1016/j.ejso.2016.07.138
pubmed: 27769634
Jena S, Bhattacharya S, Gupta A, Sinha NK. Axillary reverse mapping in patients undergoing axillary lymph node dissection: a single-institution experience from India. Cereus. 2021;13:1–9.
Caudle AS, Yang WT, Krishnamurthy S, et al. Improved axillary evaluation following neoadjuvant therapy for patients with node-positive breast cancer using selective evaluation of clipped nodes: implementation of targeted axillary dissection. J Clin Oncol. 2016;34:1072–8.
doi: 10.1200/JCO.2015.64.0094
pubmed: 26811528
pmcid: 4933133
Barrio AV, Montagna G, Mamtani A, et al. Nodal recurrence in patients with node-positive breast cancer treated with sentinel node biopsy alone after neoadjuvant chemotherapy: a rare event. JAMA Oncol. 2021;7:1851–5.
doi: 10.1001/jamaoncol.2021.4394
pubmed: 34617979
Ma X, Wen S, Liu B, et al. Relationship between upper extremity lymphatic drainage and sentinel lymph nodes in patients with breast cancer. J Oncol. 2019;2019:1–7.
doi: 10.1155/2019/8637895